Related Experiment Video
Updated: Feb 14, 2026

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
Published on: December 9, 2016
A cross-sectional study examining the expression of splice variants K-RAS4A and K-RAS4B in advanced non-small-cell
Veronica Aran1, Pedro Masson Domingues1, Fabiane Carvalho de Macedo2
1Clinical Research Division, Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil.
Objectives:
Mammalian cells differently express 4 RAS isoforms: H-RAS, N-RAS, K-RAS4A and K-RAS4B, which are important in promoting oncogenic processes when mutated. In lung cancer, the K-RAS isoform is the most frequently altered RAS protein, being also a difficult therapeutic target. Interestingly, there are two K-RAS splice variants (K-RAS4A and K-RAS4B) and little is known about the role of K-RAS4A. Most studies targeting K-RAS, or analysing it as a prognostic factor, have not taken into account the two isoforms. Consequently, the in-depth investigation of them is needed.
Methods:
The present study analysed 98 specimens from advanced non-small cell lung cancer (NSCLC) adenocarcinoma patients originated from Brazil. The alterations present in K-RAS at the DNA level (Sanger sequencing) as well as the expression of the splicing isoforms at the RNA (qRT-PCR) and protein levels (immunohistochemistry analysis), were evaluated. Possible associations between clinicopathological features and the molecular findings were also investigated.
Results:
Our results showed that in the non-smoking population, the cancer incidence was higher among women. In contrast, in smokers and former smokers, the incidence was higher among men. Regarding sequencing results, 10.5% of valid samples presented mutations in exon 2, being all wild-type for exon 3, and the most frequently occurring base change was the transversion G → T. Our qRT-PCR and immunohistochemical analysis showed that both, K-RAS4A and K-RAS4B, were differently expressed in NSCLC tumour samples. For example, tumour specimens showed higher K-RAS4A mRNA expression in relation to commercial normal lung control than did K-RAS4B. In addition, K-RAS4B protein expression was frequently stronger than K-RAS4A in the patients analysed.
Conclusion:
Our results highlight the differential expression of K-RAS4A and K-RAS4B in advanced adenocarcinoma NSCLC patients and underline the need to further clarify the enigma behind their biological significance in various cancer types, including NSCLC.
Insights
This study investigated K-RAS4A and K-RAS4B expression in lung cancer, finding differential expression of these isoforms. Further research is needed to understand their biological significance in cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Mammalian cells express four RAS isoforms (H-RAS, N-RAS, K-RAS4A, K-RAS4B), with mutations promoting oncogenesis.
- K-RAS is the most frequently altered RAS isoform in lung cancer and a challenging therapeutic target.
- Little is known about the specific role of the K-RAS4A splice variant.
Purpose of the Study:
- To investigate the differential expression of K-RAS4A and K-RAS4B isoforms in advanced non-small cell lung cancer (NSCLC) adenocarcinoma.
- To analyze K-RAS DNA alterations and correlate them with clinicopathological features.
- To explore the distinct roles of K-RAS4A and K-RAS4B in NSCLC.
Main Methods:
- Analysis of 98 advanced NSCLC adenocarcinoma specimens from Brazil.
- K-RAS DNA alterations assessed via Sanger sequencing.
- K-RAS4A and K-RAS4B expression evaluated at RNA (qRT-PCR) and protein (immunohistochemistry) levels.
Main Results:
- In non-smokers, cancer incidence was higher in women; in smokers, it was higher in men.
- 10.5% of samples had K-RAS mutations (exon 2), with G→T transversion being most common.
- Both K-RAS4A and K-RAS4B showed differential expression in NSCLC tumors; K-RAS4A mRNA was higher, while K-RAS4B protein expression was often stronger.
Conclusions:
- K-RAS4A and K-RAS4B exhibit distinct expression patterns in advanced NSCLC adenocarcinoma.
- The biological significance of these differential expressions warrants further investigation across various cancer types.
- Understanding isoform-specific roles is crucial for targeted therapies in lung cancer.
Related Concept Videos
Cross-Sectional Research
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
RNA Splicing
Finding Volume Using Cross-Sectional Area
Profile Leveling and Cross Sections
Spinal Cord: Cross-sectional Anatomy
Gray Matter and its Components
Central to the gray matter is...

